Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Bleximenib |
Trade Name | |
Synonyms | JNJ 75276617|JNJ75276617|JNJ-75276617 |
Drug Descriptions |
Bleximenib inhibits the interaction between menin and MLL, leading to decreased expression of target genes, which potentially inhibits proliferation of tumor cells harboring KMT2A rearrangements or NPM1 mutations (PMID: 38905635). |
DrugClasses | MEN1-KMT2A Inhibitor 8 |
CAS Registry Number | 2654081-35-1 |
NCIT ID | C179561 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + Bleximenib | Azacitidine Bleximenib | 0 | 1 |
Azacitidine + Bleximenib + Venetoclax | Azacitidine Bleximenib Venetoclax | 0 | 1 |
Bleximenib | Bleximenib | 0 | 1 |
Bleximenib + Cytarabine + Dexamethasone + Fludarabine + Pegaspargase + Vincristine Sulfate | Bleximenib Cytarabine Dexamethasone Fludarabine Pegaspargase Vincristine Sulfate | 0 | 1 |
Bleximenib + Gilteritinib | Bleximenib Gilteritinib | 0 | 0 |
Bleximenib + Venetoclax | Bleximenib Venetoclax | 0 | 1 |